Remove 2025 Remove Biosimilars Remove Pharmaceutical Manufacturing
article thumbnail

Bioprocessing / Bioproduction In-Depth Focus 2025

European Pharmaceutical Review

Unlocking Europe’s biomanufacturing potential Glenn Gerecke, Chief Manufacturing and Supply Officer, Sandoz, discusses how Europe can meet the rising demand for biosimilars and support biomanufacturing in the region.

article thumbnail

Pharmaceutical Technology Excellence Awards 2025: i3 Membrane

Pharmaceutical Technology

Can pharma tariffs “Make America Manufacture Again”? This flexibility is particularly beneficial for pharmaceutical manufacturers looking to upgrade their research and discovery processes without overhauling their entire systems. “Great thanks to Pharmaceutical Technology. Login Registration is disabled.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Bayer’s Eylea market grip set to slip as Alvotech biosimilar closes in

Pharmaceutical Technology

Robert Barrie June 23, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook Bayer’s Eylea is a heavyweight of the ophthalmic drug landscape, approved for a range of eye diseases. Go deeper with GlobalData Reports LOA and PTSR Model - Aflibercept Biosimilar in Age Related Macular. CucuMberStudio via Shutterstock.

article thumbnail

AI-driven drug discovery, precision medicine, and sustainable manufacturing can redefine the pharma industry

Express Pharma

What are the top 3 trends that defined pharma manufacturing in India and globally in 2024? In 2024, the pharmaceutical manufacturing landscape underwent transformative changes, driven by technological innovations, regulatory adaptations, and evolving global demands. and Europe. and Europe.

article thumbnail

Changing the PAP Model

Pharmaceutical Commerce

24 Hours in the Hub Still Matters More Chris Dowd, ConnectiveRx June 16th 2025 Article Doubling down on patient access and support fundamentals will win out over Washington’s next move.

article thumbnail

Bolstering Health Technology Assessment With the Help of AI

Pharmaceutical Commerce

Fast-Tracking the Future Nicholas Saraceno, Editor ; Don Tracy, Associate Editor April 25th 2025 Podcast Claire Riches highlights inefficiencies in the current drug approval process, while outlining the role of payers and insurers in shifting toward data-driven approval framework. Serialization 2.0:

article thumbnail

HPM Grows Its Ranks of Directors, Counsel, and Associates as it begins its 45th Anniversary Year

FDA Law Blog: Biosimilars

Hyman, Phelps & McNamara PC, (HPM), which will mark its 45thAnniversary on March 17, 2025, is pleased to announce that it is increasing its directors, counsel, and associates as it starts the year. Richardson has been promoted to Director. Kalie is the quintessential HPM lawyer.